Mundipharma And Cidara Therapeutics Receive Positive CHMP Opinion For Rezafungin For The Treatment Of Invasive Candidiasis In Adults
Portfolio Pulse from Benzinga Newsdesk
MundiPharma and Cidara Therapeutics have received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for Rezafungin, a treatment for invasive candidiasis in adults. This is a significant step towards the approval of the drug in the European Union.
October 13, 2023 | 2:22 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cidara Therapeutics' stock may see a positive impact as the positive CHMP opinion for Rezafungin brings the drug closer to approval in the EU.
The positive opinion from CHMP is a significant step towards the approval of Rezafungin in the EU. This could potentially open up a new market for the drug, which would likely increase Cidara Therapeutics' revenues and have a positive impact on its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100